Search Results
May 21, 2026, 21:00 ET BAI Capital annonce la première clôture d'un nouveau fonds de 800 millions de dollars, et continue de soutenir les opportunités de croissance et de mondialisation en Asie
profondément reconnaissants de la confiance et du soutien continus de nos investisseurs actuels et nouveaux. Aujourd'hui, l'environnement d'investissement met plus que jamais l'accent sur la validation, la livraison et la discipline. L'objectif principal du nouveau fonds de BAI n'est pas de poursuivre des concepts
More news about: BAI Capital
May 21, 2026, 18:47 ET Tharaldson Ethanol Increases Oil Recovery with New Technology
Ethanol successfully installed and is operating two Prodec 65 Oil Plus centrifuges as a trial project and, after six months of operation, the results met expectations to move forward with a full capital project implementation. "We are partnering with Alfa Laval and their technology and expertise
More news about: Tharaldson Ethanol
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
tumors and patient populations, including previously presented data in lung, colorectal and gastric cancers and across patients with MET-amplification and increased c-Met expression.Relapsed/refractory multiple myeloma (R/R MM): Data from a Phase 1b study
More news about: AbbVie
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
community."Key highlights from the presentations at ASCO and EHA include:In the Phase 3 AcceleRET clinical trial, pralsetinib met the primary progression-free survival (PFS) endpoint and had a significantly greater overall response rate and more durable response vs. standard of
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
2025.Separately, at the American Association for Cancer Research (AACR) Annual Meeting, Johnson & Johnson disclosed JNJ‑95437446, an amivantamab-based EGFR/MET ADC that uses CPT113. In the poster, JNJ‑95437446 reported preclinical findings that support its ongoing Phase 1 clinical development (
More news about: Whitehawk Therapeutics, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
LIBRETTO-432 study of adjuvant selpercatinib in patients with stage IB-IIIA RET fusion-positive NSCLC. Lilly previously announced that selpercatinib met the primary endpoint, demonstrating a highly significant and clinically meaningful improvement in investigator-assessed event free survival. These results
More news about: Eli Lilly and Company
May 21, 2026, 16:54 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studiesSTOCKHOLM,
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:51 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studiesSTOCKHOLM,
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:10 ET Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
trenibotulinumtoxinE in adult subjects with moderate to severe glabellar lines (M21-500 and M21-508). All primary and secondary endpoints of the Phase 3 studies were met, with a rapid onset of action as early as eight hours after administration (the earliest assessment time) and observed efficacy duration for two to three
More news about: AbbVie
May 21, 2026, 16:05 ET Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from
More news about: INOVIO Pharmaceuticals, Inc.
May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
results from a phase 2/3 study evaluating its drug tovecimig as a biliary tract cancer treatment. Although the press release emphasized that the study "met the key secondary endpoint of [progression-free survival] and showed additional compelling results", the study also missed another key secondary endpoint,
More news about: Pomerantz LLP
May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alstom S.A. - ALSMY; AOMFF
three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year. Following these disclosures, Alstom's stock price fell sharply, damaging investors.Pomerantz LLP, with
More news about: Pomerantz LLP
May 21, 2026, 15:03 ET Dự án Tân Hội, Giang Môn của SUS ENVIRONMENT tái định hình mạch sinh thái của các đô thị xanh
trên Con đường tơ lụa trên biển cổ đại. Đội ngũ thiết kế đã sử dụng cánh buồm làm hình tượng kiến trúc chủ đạo, với quần thể công trình dài gần 800 mét trông giống như những cánh buồm căng gió. Mặt dựng nhôm kính khúc xạ ánh sáng lấp lánh như những gợn sóng trên mặt nước. Thiết kế này phá vỡ hiệu ứng
More news about: Shanghai SUS Environment Co., Ltd.
May 21, 2026, 14:56 ET Eightco Holdings (NASDAQ : ORBS) annonce un total d'environ 337 millions de dollars en avoirs, dont OpenAI, Beast Industries, plus de 11 000 ETH et plus de 283 millions de tokens WLD
de plus en plus rares.À propos de Eightco Holdings Inc.Eightco Holdings Inc. (NASDAQ : ORBS) est une société cotée en bourse qui met en œuvre une stratégie de trésorerie Worldcoin (WLD) unique en son genre, offrant aux investisseurs une exposition indirecte à trois des tendances déterminantes
More news about: Eightco Holdings (NASDAQ: ORBS)
May 21, 2026, 14:02 ET VINFAST PRÉSENTE SUR LE MARCHE VIETNAMIEN LA NOUVELLE GÉNÉRATION DU VF 8
développé selon la philosophie « Tech Fluid », qui intègre la technologie au langage stylistique du véhicule et à son utilisation au quotidien. Le design met l'accent sur la fluidité et une impression de mouvement, créant l'apparence d'un SUV moderne et dynamique qui reflète un style de vie contemporain.Le
More news about: VinFast
May 21, 2026, 13:19 ET Un rapport de HCLTech met en garde sur le fait que 43 % des initiatives d'IA en entreprise risquent d'échouer car les dirigeants sont soumis à des pressions de plus en plus fortes sur les délais de présentation de résultats
dirigeantes des entreprises à l'heure actuelle.Pour les DSI et les responsables technologiques, ces résultats révèlent à quel point l'expansion de l'IA met en évidence des contraintes cachées au sein des parcs d'applications, des environnements de données et des modèles d'exploitation qui n'ont pas été conçus
More news about: HCLTech
May 21, 2026, 10:40 ET Các thương hiệu hàng đầu, nguồn cung ứng trực tiếp từ nhà máy và xu hướng phong cách sống thúc đẩy đà tăng trưởng tại Hội chợ Quà tặng Thâm Quyến của RX Huabo
Dương dành cho ngành quà tặng và gia dụng. Được tổ chức bởi RX Huabo, sự kiện kéo dài bốn ngày này quy tụ 4.500 đơn vị triển lãm trên diện tích 300.000 mét vuông và thu hút hơn 300.000 lượt người mua tham dự, trưng bày các sản phẩm thuộc hơn 30 ngành hàng tiêu dùng, bao gồm sản phẩm gia dụng và phong cách
More news about: RX Huabo
May 21, 2026, 10:17 ET Haier ký thỏa thuận tài trợ 4 năm với Al Ahly FC, trở thành nhà tài trợ chính thứ hai của câu lạc bộ
Ai Cập tại Thành phố ngày 10 tháng Ramadan (10th of Ramadan City) là tổ hợp công nghiệp đầu tiên của công ty tại Châu Phi, có diện tích hơn 200.000 mét vuông với tổng vốn đầu tư 185 triệu USD. Giai đoạn một, bao gồm các dây chuyền sản xuất điều hòa không khí, tivi và máy giặt, đã đạt công suất vượt 900.000
More news about: Haier
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
investigator's choice of chemotherapy as first‑line treatment for unresectable locally recurrent or metastatic triple‑negative breast cancer (TNBC) has met its primary endpoint of progression‑free survival (PFS) at a prespecified interim analysis, demonstrating a statistically significant and clinically
More news about: Kelun-Biotech
May 21, 2026, 09:00 ET Blockchain.com kondigt vertrouwelijke indiening aan van een ontwerpregistratieverklaring voor voorgestelde initiële openbare aanbieding van gewone Klasse A-aandelen
het vertrouwelijk een ontwerpregistratieverklaring op formulier S-1 heeft ingediend bij de Amerikaanse Securities and Exchange Commission (de "SEC") met betrekking tot het voorgestelde initiële openbare aanbod van zijn gewone Klasse A-aandelen. Het aantal aan te bieden aandelen en de prijsmarge voor het
More news about: Blockchain.com
May 21, 2026, 09:00 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
the price of Gossamer shares down by 80%.After the Class Period, on April 9, 2026, the company revealed that since February 24, 2026 it has not met the minimum share bid price ($1) required for continued listing on the Nasdaq Global Select Market."We're focused on whether Gossamer may have
More news about: Hagens Berman Sobol Shapiro LLP
May 21, 2026, 06:45 ET Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
obesity or overweight and at least one weight-related comorbidity and without diabetes. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss."Obesity is a chronic disease, and people living
More news about: Eli Lilly and Company
May 21, 2026, 06:00 ET Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
versus axitinib or everolimus monotherapy for the second-line treatment of patients with locally advanced or metastatic renal cell carcinoma. The study met its primary endpoint of progression free survival (PFS) as assessed by blinded independent central review (BICR)."The rapid advancements in targeted
More news about: Innovent Biologics
May 21, 2026, 02:39 ET Tineco célèbre la nouvelle génération de nettoyage intelligent avec la campagne exclusive "S9 Family"
ONE S9 Artist TurboFLOOR ONE S9 ArtistScientist Series : l'innovation au service de la précisionLa série Scientist met l'accent sur la technologie avancée et la précision du nettoyage. Grâce à des fonctionnalités intelligentes et une optimisation des performances, elle
More news about: Tineco
May 21, 2026, 01:30 ET QWEEN Makes a Striking Global Debut at the Met Gala with Diya Mehta
NEW DELHI, May 21, 2026 /PRNewswire/ -- At this year's Met Gala, celebrity stylist and fashion influencer Diya Mehta made a striking appearance in bespoke high jewellery pieces by QWEEN, marking the brand's first outing
More news about: QWEEN